Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications

Kato, Toshiro; Vykoukal, Jody; Fahrmann, Johannes F.; Hanash, Samir M.

doi:10.3390/cancers13184604

Cited by 12 publications

(8 citation statements)

References 103 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pleural effusion-derived EVs are considered to be valuable biomarkers for early molecular diagnosis of lung cancer, tuberculosis and other diseases ( Wang et al, 2017 ; Luo et al, 2020 ; Javadi et al, 2021 ; Kato et al, 2021 ). The effective methods for isolating high-purity EVs remain a major challenge, which limits the application of EVs in early disease diagnosis and clinical translation.…”

Section: Discussionmentioning

confidence: 99%

Comparison of proteomic landscape of extracellular vesicles in pleural effusions isolated by three strategies

Yao

Liao

Chen

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Graphical AbstractIn our study, three methods were used for isolating extracellular vesicles derived from pleural effusion (pEVs), including ultracentrifugation (UC), a combination of UC and size exclusion chromatography (UC-SEC) and a combination of UC and density gradient ultracentrifugation (UC-DGU), and followed with proteomics analysis. Our results show that the method of UC-SEC could significantly improve the purity of pEVs and improve the performance of proteomic analysis of pEVs. The exosomal proteins CD11C, HLA DPA1 and HLA DRB1 may act as potential markers of pEVs.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of proteomic landscape of extracellular vesicles in pleural effusions isolated by three strategies

Yao

Liao

Chen

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Exosomes from cancer cells can be exploited as a communication tool with local and distant normal cells to generate a micro-environment suitable for their proliferation/invasion. For instance, lung cancer cell-derived exosomes were able to induce a pro-inflammatory phenotype in mesenchymal stem cells that in turn support tumor growth ( 93 ).…”

Section: Role Of Evs In Cancer Cell-tumor Microenvironment Crosstalk ...mentioning

confidence: 99%

The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment

et al. 2023

View full text Add to dashboard Cite

Lung cancer is the deadliest cancer in the world, with the majority of patients presenting with advanced or metastatic disease at first diagnosis. The lungs are also one of the most common sites of metastasis from lung cancer and other tumors. Understanding the mechanisms that regulate metastasis formation from primary lung cancer and in the lungs is therefore fundamental unmet clinical need. One of the first steps during the establishment of lung cancer metastases includes the formation of the pre-metastatic niche (PMN) at distant organs, which may occur even during the early phases of cancer development. The PMN is established through intricate cross-talk between primary tumor-secreted factors and stromal components at distant sites. Mechanisms controlling primary tumor escape and seeding of distant organs rely on specific properties of tumor cells but are also tightly regulated by interactions with stromal cells at the metastatic niche that finally dictate the success of metastasis establishment. Here, we summarize the mechanisms underlying pre-metastatic niche formation starting from how lung primary tumor cells modulate distant sites through the release of several factors, focusing on Extracellular Vesicles (EVs). In this context, we highlight the role of lung cancer-derived EVs in the modulation of tumor immune escape. Then, we illustrate the complexity of Circulating Tumor Cells (CTCs) that represent the seeds of metastasis and how interactions with stromal and immune cells can help their metastatic dissemination. Finally, we evaluate the contribution of EVs in dictating metastasis development at the PMN through stimulation of proliferation and control of disseminated tumor cell dormancy. Overall, we present an overview of different steps in the lung cancer metastatic cascade, focusing on the EV-mediated interactions between tumor cells and stromal/immune cells.

show abstract

“…EVs are nanosized, spherical, lipid‐bound membranous entities that contain a variety of biomolecules, including proteins, nucleic acids, lipids, and metabolites (Simeone et al, 2020; Zaborowski et al, 2015). These multifaceted structures perform intricate roles in cell‐to‐cell communication and may be derived from a wide range of cell types (Kato et al, 2021). Notably, EVs are present in various bodily fluids, including blood, urine, saliva, amniotic fluid, semen, cerebrospinal fluid, and breast milk, as well as tissues and cell culture supernatants (Wu et al, 2021).…”

Section: The Beneficial Characteristics Of Mscsmentioning

confidence: 99%

“…EVs are nanosized, spherical, lipid-bound membranous entities that contain a variety of biomolecules, including proteins, nucleic acids, lipids, and metabolites (Simeone et al, 2020;Zaborowski et al, 2015). These multifaceted structures perform intricate roles in cell-to-cell communication and may be derived from a wide range of cell types (Kato et al, 2021).…”

Section: Evsmentioning

confidence: 99%

Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Saadh,

Alhuthali,

Gonzales Aníbal

et al. 2023

Cell Biology International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are recognized for their remarkable ability to differentiate into multiple cell types. They are also known to possess properties that can fight cancer, leading to attempts to modify MSCs for use in anticancer treatments. However, MSCs have also been found to participate in pathways that promote tumor growth. Many studies have been conducted to explore the potential of MSCs for clinical applications, but the results have been inconclusive, possibly due to the diverse nature of MSC populations. Furthermore, the conflicting roles of MSCs in inhibiting tumors and promoting tumor growth hinder their adaptation to anticancer therapies. Antitumorigenic and protumorigenic properties of MSCs in urological cancers such as bladder, prostate, and renal are not as well established, and data comparing them are still limited. MSCs hold significant promise as a vehicle for delivering anticancer agents and suicide genes to tumors. Presently, numerous studies have concentrated on the products derived from MSCs, such as extracellular vesicles (EVs), as a form of cell‐free therapy. This work aimed to review and discuss the current knowledge of MSCs and their EVs in urological cancer therapy.

show abstract

Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications

Cited by 12 publications

References 103 publications

Comparison of proteomic landscape of extracellular vesicles in pleural effusions isolated by three strategies

Comparison of proteomic landscape of extracellular vesicles in pleural effusions isolated by three strategies

The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment

Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Contact Info

Product

Resources

About